Info

BioXell SpA is an Italy-based biopharmaceutical company. The Company focuses on the research, development and commercialization of therapies for various medical needs. It is active in a range of therapeutic areas, such as urology (benign prostatic hyperplasia, overactive bladder and male infertility), inflammation (sepsis, inflammatory bowel disease, post-surgical adhesions), pain and other therapeutic areas (secondary hyperparathyroidism and osteoporosis). BioXell S.p.A’s products, which are in the preclinical and development phases, include Elocalcitol and BXL746, a Vitamin D3 analogues for the treatment of urological disorders; MNAC13 applied for treatment of chronic pain, and TREM-1, for the treatment of sepsis. The Company has one wholly owned subsidiary, BioXell Inc that develops the Vitamin D3 platform.